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Bone defects often result from tumor resection, congenital malformation,trauma, fractures, surgery, or periodontitis in dentistry.
Although dental implants serve as an eﬀective treatment to recover mouth function from tooth defects, many patients do not
have the adequate bone volume to build an implant. The gold standard for the reconstruction of large bone defects is the use
of autogenous bone grafts. While autogenous bone graft is the most eﬀective clinical method, surgical stress to the part of the
bone being extracted and the quantity of extractable bone limit this method. Recently mesenchymal stem cell-based therapies
have the potential to provide an eﬀective treatment of osseous defects. In this paper, we discuss both the current therapy for bone
regeneration and the perspectives in the ﬁeld of stem cell-based regenerative medicine, addressing the sources of stem cells and
growth factors used to induce bone regeneration eﬀectively and reproducibly.
1.Introduction
Regenerative medicine is the medical ﬁeld that creates func-
tional tissues to repair and replace damaged or malfunction-
ing tissues and organs [1]. Tissues or organs generated from
a patient’s own cells would allow transplants without tissue
rejection. Furthermore, regenerative medicine treatments
have the potential to replace organ transplants or artiﬁcial
organs. Because regenerative medicine generates tissues or
organs using engineering technology, it is also called “tissue
engineering.” To make regenerative medicine successful,
three elements are required: stem cells, scaﬀolds, and growth
factors [1]. Translational research, which takes results from
the laboratory and translates them to the clinics, and in-
dustry-academic collaborations also play important roles in
making regenerative medicine suitable for practical use.
The human skeletonconsistsofapproximately200 bones,
and it weighs approximately2kg.Bone isa toughsupporting
tissue and functions in both movement and the maintenance
of postural stability by working cooperatively with muscles.
Bones also play an important role in calcium metabolism.
Despite its hard structure, bone actually exists in a constant
state of dynamic turnover known as bone remodeling [2]
(Figure 1). There are two types of bone structures, cortical
bone and cancellous bone. The ratio of the cortical bone
and the cancellous bone of an adult is 9:1. Approximately
3% of the cortical bone is remodeled per year, whereas more
than 30%ofthecancellousboneisremodeled peryear. Thus,
approximately 6% of all human bones will be remodeled in a
year. The bone mass in an adult human reaches its maximal
level (peak bone mass) during a person’s twenties and then
gradually declines thereafter, as the speed of bone resorption2 International Journal of Dentistry
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Figure1:Theschematicoutlinesoftheboneremodelingcycleandthebalanceofboneresorptionandboneformation.(a)Inbonetissue,the
osteoblasts are involved in new bone formation,while osteoclastsplay a majorrole in bone resorption. The ﬁrst step in the bone remodeling
cycle is the resorption of existing bone by osteoclasts, followed by formation of the cement line in resorption lacunae and osteoblasts. Each
cell type seems to be regulated by a variety of hormones and by local factors. (b) If the balance between bone formation and resorption
is lost by the uncontrolled production of regulators, bone structure would be strikingly damaged, and the subject would be susceptible to
osteoporosis and osteopetrosis.
exceeds bone formation with increasing age. Although bone
mass in humans decreases by approximately 1% per year,
the bone mass in women entering menopause will decrease
by approximately 3% per year. At the remodeling sites,
osteoblasts produce new bone, while osteoclasts resorb exist-
ing bone. Each cell type seems to be regulated by a variety of
hormones and by local factors. If the balance between bone
formation and resorption is lost by uncontrolled production
of these regulators, the bone structure will be damaged,
and the subject would be susceptible to osteoporosis and
osteopetrosis [2]( Figure 1).
Bone defects often result from tumor resection, congeni-
talmalformation, trauma,fractures, surgery,orperiodontitis
in dentistry, as well as from diseases, such as osteoporosis or
arthritis. The gold standard for reconstruction of large bone
defectsis the use of autogenous bone grafts [3]. This method
has signiﬁcant limitations, such as a lack of suﬃcient trans-
plantablematerials, donorsite morbidity,inﬂammation, and
resorption of the implanted bone. Although alternatives,
such as the use of allografts or synthetic grafting materials,
address these limitations, both alternatives are also limited
by immunogenesis or lack of osteoinductivity [4].
Thediscoveryofstemcellsandrecentadvancesincellular
and molecular biology have led to the development of novel
therapeutic strategies that aim to regenerate tissues that
were injured by disease. Recently, embryonic stem cells (ES
cells) [5], induced pluripotent stem cells (iPS cells) [6], and
somatic stem cells have been reported; however, there are
many issues to overcome for the clinical use of ES and iPS
cells, including ethical and safety problems, immunorejec-
tion, and tumorigenesis.
This review discusses the current therapies for bone re-
generation and perspectives in the ﬁeld of stem cell-based
regenerative medicine, addressing sources of stem cells and
growth factors to develop an eﬃcient and high-quality bone
derivation without any immunorejection, and tumorigene-
sis. Wealso discuss thepotentialuseof regenerativemedicine
in dental tissue engineering.
2.CurrentStatusofBone Regenerationin
Dentistry
Chronic dental disease and tooth loss often lead to the loss
of hard tissue in the jaw. Patients with missing teeth by
infections, or inﬂammation may experience bone resorption
with lossoftheaﬀectedpart ofthe jaw. Inadditiontomaking
a patient uncomfortable, this bone loss can cause unsightly
disﬁgurements and may complicate the ﬁtting of implants
and other dental appliances. Although dental implants serve
as an eﬀective treatment to recover mouth function from
tooth defects, many patients do not have adequate bone
volume to build an implant. The outline of the current
method to increase bone volume is described.
2.1. Bone Grafts and Artiﬁcial Bone Materials. Although the
autogenous bone graft is the most eﬀective clinical method
for bone repair, it can be restricted by surgical stress to the
site of bone extraction and the quantity of extractable bone.
Demineralized and freeze-dried bone (DFDBa) extracted
from the body is used for xenogamous bone grafts [3, 4].
Hydroxyapatite or various forms of β-tricalcium phos-
phate (β-TCP) are used as artiﬁcial bone materials [7]. Be-
cause these calcium phosphate materials do not have bone
guidance capability, they are used together with autogenous
bone grafts or other bone increasing methods, such as the
guided bone regeneration (GBR) method and platelet-rich
plasma (PRP).International Journal of Dentistry 3
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Figure 2: A schematic model for the diﬀerentiation of mesenchymal stem cells into tissue-speciﬁc cells by speciﬁc transcriptional factors.
Mesenchymalstemcellscandiﬀerentiateintoosteoblasts,chondrocytes,myoblasts,andadipocytes.Eachdiﬀerentiationprogramisregulated
by speciﬁc transcription factors: Runx2/Osterix, Sox5/6/9,MyoD family, and PPARγ, respectively.
2.2. Guided Bone Regeneration: GBR. Guided bone regener-
ation (GBR) encourages new bone growth to replace areas
of damage in the jaw and can be used alongside guided
tissue regeneration (GTR) to rebuild soft tissue in a patient’s
mouth [8]. The technologies and practices behind these
techniques are subject to constant reﬁnement, and clinical
studies examine the possible application of these techniques
to other regions of the body. GBR involves epithelial and
connective tissue exclusion and space creation to allow the
cells of the periodontal ligament to repopulate the root
surface and to allow bone cells to grow into the area of the
defect. GBR is usually performed together with a bone graft
or PRP. Although this method induces self-regeneration of
bone, it takes a long time to obtain adequate bone volume in
many cases.
2.3. Distraction Osteogenesis. Distraction osteogenesis is a
well-established technique used by orthopedic surgeons
to repair long bone defects without the use of grafting
materials and has gained acceptance over the past 15 years
for the correction of various craniofacial deformities [9].
Several studies in various animal models demonstrated the
application of osteodistraction at a number of diﬀerent sites,
including the mandible, the maxilla, the midface, and the
cranial vault. There are several advantages of distraction
osteogenesis over conventional osteotomy: operative times
and blood loss are reduced, bone grafts are unnecessary,
and bone is distracted in conjunction with the surrounding
soft tissues and nerves. However, distraction osteogenesis
has some disadvantages, such as technique-sensitive and
equipment-sensitive surgery, and the possible need for a
second surgery to remove distraction devices and patient
compliance.
2.4. Platelet-Rich Plasma: PRP. In the ﬁeld of dentistry, PRP
has been used in diﬀerent clinical procedures, such as sinus
ﬂoor elevation, alveolar ridge augmentation, mandibular
reconstruction, maxillary cleftrepair, treatmentofperiodon-
tal defects, and treatment of extraction sockets, where it has
been applied alone or in addition to the autogenous bone,
anorganic bone mineral, and organic bone substitutes [10].
The growth factors present in PRP are thought to contribute
tothebone-healing process.Thefollowing growthfactorsare
reported to be present in PRP: platelet-derived growth factor
(PDGF), transforming growth factor-β (TGF-β), vascular
endothelial growth factor (VEGF), epithelial growth factor
(EGF), insulin growth factor-1 (IGF-1), and basic ﬁbroblast
growth factor (bFGF). In addition, three blood proteins,
ﬁbrin, ﬁbronectin, and vitronectin, are known to act as cell
adhesion molecules for osteoconduction [11, 12]. Therefore,
PRP may inﬂuence bone formation through a variety of
pathways.
3.A Cell-Based TherapyforBone
RegenerationinDentistry
In recent years, stem cell research has grown exponentially
duetotherecognitionthatstemcell-based therapieshavethe
potential to improve the life of patients with several kinds of
diseases, such as Alzheimer’s disease and cardiac ischemia.
These therapies have also a role in regenerative medicine,
such as the repair of bone or tooth loss. Stem cells have
the potential to diﬀerentiate into several cell types, including
o d o n t o b l a s t s ,n e u r a lp r o g e n i t o r s ,o s t e o b l a s t s ,c h o n d r o c y t e s ,
and adipocytes (Figure 2). Mesenchymal stem cells (MSC)
are multipotent progenitor cells that were originally isolated
from various tissues, including adult bone marrow, adipose
tissue, skin, umbilical cord, and placenta. Bone marrow-
derivedMSCshavebeenusedinclinicaltrialsfortheeﬀective
treatment of osseous defects. However, bone marrow aspira-
tion is an invasive and painful procedurefor thedonorand is
ad i ﬃcult procedure for a general practitioner. Furthermore,4 International Journal of Dentistry
MSCs constitute heterogeneous cell types, and the potential
for proliferation and diﬀerentiation of the MSCs depends
on a patient’s age, sex, or the presence of certain medical
conditions, such as diabetes or hypertension [13].
Several cell populations with stem cell properties have
been isolated from diﬀerent parts of the tooth, including
the pulp of both exfoliated and adult teeth, the periodontal
ligament, and the dental follicle. Dental pulp stem cells
(DPSCs) [14] and stem cells from human exfoliated decid-
uous teeth (SHED) [15] have generic mesenchymal stem
cell-like properties, such as self-renewal and multilineage
diﬀerentiation.DPSCsandSHEDhavetheabilitytogenerate
not only dental tissue but also bone tissue. Because SHED
exhibit higher proliferation rates and can be obtained with
ease compared to bone marrow-derived MSCs, they might
becomeanattractivesource ofautologousstemcellsforbone
regeneration. As described above, MSCs are heterogeneous
cell populations; therefore, to induce bone regeneration ef-
fectively and reproducibly, it is important to understand the
mechanisms by which growth factors or cytokines regulate
osteoblast diﬀerentiation.
3.1. Regulation of Osteoblast Diﬀerentiation. Bone consists
of hydroxyapatite crystals and various kinds of extracellular
matrix proteins, including type I collagen, osteocalcin,
osteopontin, bone sialoprotein and proteoglycans. Most of
these bone matrix proteins are secreted and deposited by
mature osteoblasts, which are aligned on the bone surface
[2, 16]. The formation of hydroxyapatite crystals in osteoids
is also regulated by osteoblasts. Therefore, the expression
of a number of bone-related extracellular matrix proteins,
the high enzyme activity of alkaline phosphatase (ALP)
by responses to osteotropic hormones and cytokines are
believed to be major characteristics of osteoblasts [2, 16].
It is well known that osteoblasts, chondrocytes, adipo-
cytes, myoblasts, tendon cells, and ﬁbroblasts are diﬀerenti-
ated from common precursors in the bone marrow-derived
MSCs.The lineagesaredeterminedbydiﬀerenttranscription
factors. The transcription factors Runx2, Osterix, or β-
catenin regulate osteoblast diﬀerentiation, the Sox family of
transcription factors (Sox9, Sox5, and Sox6) regulate chon-
drocyte diﬀerentiation, MyoD transcription factors (MyoD,
Myf5 and Myogenin) regulate myogenic diﬀerentiation, and
the C/EBP family (C/EBPβ,C / E B P δ,a n dC / E B P α)a n d
PPARγ transcription factors regulate adipocyte diﬀerenti-
ation (Figure 2). Runx2 directs multipotent mesenchymal
cells to an osteoblastic lineage, and β-catenin, Osterix, and
Runx2 direct them to mature osteoblasts after diﬀerentiation
to preosteoblasts [2, 16, 17].
Several hormones and cytokines, such as bone morpho-
genetic proteins (BMP), TGF-β,W n t ,h e d g e h o g ,b F G F ,a n d
estrogen, are involved in the regulation of mesenchymal cell
diﬀerentiation by stimulating intracellular signaling path-
w a y s .A m o n gt h e m ,B M Pi so n eo ft h em o s tp o w e r f u lc y t o -
kines to induce ectopic bone formation, and it strongly
promotes the diﬀerentiation of mesenchymal cells into os-
teoblasts.
BMPs, membersoftheTGF-βsuperfamily, wereoriginal-
lyidentiﬁedby theirabilitytoinduceectopicboneformation
when implanted into muscle tissue, and they play a pivotal
role in the signaling networks and processes associated with
skeletal morphogenesis [16, 17]. BMP signals are transduced
from the plasma membrane receptorsto thenucleusthrough
both the Smad pathway and non-Smad pathways and are
regulated by many extracellular and intracellular molecules
thatinteractwithBMPsorcomponentsoftheBMPsignaling
pathways. This bone-inducing ability of BMPs should be
useful for the development of bone regeneration. However,
BMPs cannot generate a suﬃcient clinical response to be
usedinboneregeneration.Onepossiblereason mightbethat
inﬂammatory cytokines inhibit both bone formation and
osteoblast diﬀerentiation induced by BMPs. For example,
the inﬂammatory cytokine tumor necrosis factor (TNF) α
inhibitsosteoblastdiﬀerentiationinmultiplemodels,includ-
ingfetalcalvaria,bonemarrow stromal cells,andosteoblastic
cells [18–20].
3.2. Inﬂammatory Cytokines Suppress Osteoblast Diﬀerentia-
tion. Inﬂammatory cytokines, such as TNFα or interleukin-
(IL-)1, contribute to local and systemic bone loss in
inﬂammatory bone diseases, such as rheumatoid arthritis
and periodontitis, and estrogen deﬁciency [21]. In patients
with rheumatoid arthritis, TNFα and other cytokines are
overproduced in inﬂamed joints by various cells that inﬁl-
trate the synovial membrane, and anti-TNF drugs, such as
inﬂiximab, etanercept, and adalimumab, have been shown
to not only diminish signs and symptoms of disease but
also to prevent joint damage [22]. Under these conditions,
osteoblast-mediated bone formation cannot compensate for
accelerated osteoclastic bone resorption, suggesting a direct
inhibitory eﬀect of inﬂammatory cytokines on osteoblasts.
Consistent with clinical and in vivo animal studies, the
inhibitory eﬀects of TNFα or IL-1β on bone formation in
vitro were also observed with a neonatal rat calvarial organ
culture system [16]. TNFα or IL-1β inhibited not only spon-
taneous osteoblast diﬀerentiation but also BMP-induced
osteoblast diﬀerentiation, as measured by a change in the
BMP2-induced expression of Runx and osteocalcin and a
dose-dependent change in ALP activity. These responses
were mediated via several signaling pathways, such as
mitogen-activated protein kinase (MAPK), extracellular sig-
nal regulated kinase (ERK), c-Jun N-terminal kinase (JNK),
p38 kinase, and NF-κB.
3.3. Suppression of NF-κB Enhances BMP-2-Induced Osteo-
blast Diﬀerentiation. The transcription factor NF-κBh a sa
key role in inﬂammation and immune responses. Previous
studies have shown that inhibition of NF-κB suppresses
inﬂammatory bone loss by inhibiting osteoclastogenesis in
an arthritis model, suggesting that NF-κBi sam a j o rt a r g e t
of inﬂammatory bone diseases [23]. The importance of NF-
κB in osteoblasts was revealed in a recent paper, where the
authors expressed a dominant negative form of IKKβ to
inhibit NF-κB in the mature osteoblasts of mice. Expression
of this dominant negative IKKβ led to increased BMD and
bone volumedueto theincreased activity ofosteoblasts[24].
Inhibition of NF-κB by overexpression of the dominant
negative form of IκBα (IκBαDN) leads to the induction ofInternational Journal of Dentistry 5
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Figure 4: BMP2-induced ectopic bone formation in vivo is enhanced in the presence of a selective inhibitor of NF-κB, BAY11-7082. Two
micrograms of BMP2 was implanted subcutaneously to induce ectopic bone formation in the presence or absence of BAY11-7082 in mice
(n = 8). (a) μCT reconstruction images of ectopic bone in the presence or absence of BAY11-7082 in mice. Bar: 1mm. (b) Bone mineral
density (BMD) of the ectopic bone in the presence or absence of BAY11-7082 was measured by dual-energy X-ray absorptiometry (DXA).
∗P < 0.01.
osteoblast diﬀerentiation[25]. The cell permeable NF-κBa c -
tivation antagonist TAT-NBD blocksthe activation of NF-κB
by TNFα and could prevent TNFα from suppressing TGFβ-
stimulated Smad luciferase activity, BMP2-induced Runx2
mRNA expression, and osteoblast diﬀerentiation in MC3T3-
E1 cells, a mouse osteoblastic cell line [26]. Furthermore, the
selective inhibition of NF-κB increased the bone formation
and ameliorated osteopenia in ovariectomized mice [27].We
have previously shown that TNFα inhibited BMP-induced
osteoblast diﬀerentiation through NF-κBa c t i v a t i o nb yi n -
hibiting Smad DNA binding [28]( Figure 3). Therefore, we
examined whether the selective inhibitor of NF-κB, BAY11-
7082, enhanced the ectopic bone formation induced by
BMP2 in mice. BMP2-induced ectopic bones were enlarged
and had enhanced radioplaques in the presence of BAY11-
7082 compared with BMP2 treatment alone. The μCT image6 International Journal of Dentistry
of ectopic bones induced by BMP2 together with BAY11-
7082 showed a thick outer bone ﬁlled with trabecular bone
(Figure 4(a)). The bone mineral density (BMD) of these
ectopic bones were also increased in the presence of BAY11-
7082 (Figure 4(b)). These results strongly indicate that in-
hibition of NF-κB may promote BMP-induced bone regen-
eration in the treatment of bone diseases.
4.Conclusion
Although regenerative medicine has been tried in various
ﬁelds, there is much demand for regenerative medicine in
dentistry, particularly in bone regeneration. Depending on
the state of periodontitis or jaw resection, it might take more
than 6 to 12 months for occlusal reconstitution. Thus, the
developmentofan eﬃcientandhigh-qualitybonederivation
method is necessary. Cell-based therapy may pave the way
to rejection-free regenerative treatment for bone defects.
It is also likely that research concerning growth factor or
cell-based therapies will continue to progress. However,
there are also many problems, such as laws and costs of
equipment, that must be solved. Although it is unclear when
the technology of regenerative medicine will be put into
practical use, it is important to follow the current status of
regenerative medicine to keep abreast of the progression the
technology.
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